Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Health
Adam Eckert

Why BriaCell Therapeutics Stock Is Surging Today

BriaCell Therapeutics Corp (NASDAQ:BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer.

Bria-IMT is a cell-based immunotherapy designed to selectively destroy tumor cells without harming the normal cells.

BriaCell is currently enrolling and dosing advanced breast cancer patients in a Phase 1/2a study of Bria-IMT with Incyte's checkpoint inhibitor, retifanlimab, and its immunomodulator, epacadostat in a collaboration with Incyte. The Fast Track designation will apply to patients with metastatic breast cancer. Fast Track improves the speed and frequency of communication with the FDA.

BriaCell is a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer.

See Also: Morning Brief: Top Stories Dominating Financial Media on Wednesday, April 13

BCTX 52-Week Range: $2.81 - $12.47

According to data from Benzinga Pro, the stock was up 12.1% at $11.11 at publication time.

Photo: mohamed_hassan from Pixabay.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.